A cute heart failure (HF) syndrome (AHFS) is a major reason for visits to the emergency department (ED). 1, 2 Patients with AHFS represent a heterogeneous group defined by new or worsening symptoms of HF that require urgent care. 3 Although several potential underlying or precipitating factors are implicated, ischemic heart disease contributes importantly as a pathogenetic factor in AHFS. 4 It is estimated that 50% to 70% of patients with AHFS have concomitant coronary artery disease; however, optimal management of ischemic heart disease among patients with HF presenting in the acute hospital setting has not been fully elucidated. [5] [6] [7] [8] At the current time, the management of AHFS is directed toward symptom improvement because many putative targets for acute therapy have not yielded a mortality benefit. 9-11 Recent evidence from a clinical registry suggested that patients with AHFS who underwent coronary angiography in hospital had increased use of evidence-based therapies and revascularization procedures and experienced lower mortality rates than those not undergoing the invasive procedure. 12 Furthermore, patients with AFHS who underwent coronary revascularization exhibited mortality risks that did not differ from those without coronary artery disease. 13 Although an early invasive investigation and a revascularization strategy similar to that for acute coronary syndromes provide interesting possibilities to improve survival in AHFS, randomized trials have not tested this hypothesis.
Furthermore, the risks and costs associated with these interventions limit their widespread and nonselective use. 14 Elevated cardiac troponins (cTn+) are associated with increased mortality risk in those hospitalized with AHFS. [15] [16] [17] [18] [19] They have also been shown to be one of the most important factors associated with early death in patients presenting to the ED with HF. 20 However, predictors of HF death are not necessarily equally important predictors of readmission. 21 Specifically, the importance of cTn as a predictor of future cardiovascular hospitalization has not been determined in a multicenter population-based setting. Furthermore, the clinical characteristics, diagnostic investigations, and therapeutic interventions of patients with cTn+ AHFS have not been described fully and longitudinally over time. Troponin may be an important biomarker that could identify potential HF patient subgroups that might benefit from quality improvement efforts. However, before cTn can be systematically regarded in this way, it should be demonstrated that it is associated with a wide range of adverse morbidity and mortality outcomes, investigation and treatment rates are low in those with elevated cTn, and outcomes may be altered by treatment of the higher risk group.
In this study, we compared the presenting features, processes of care, death, and hospitalization outcomes of patients presenting with cTn+ versus cTn− AHFS. In addition, we examined mortality of patients with or without elevated cTn after early coronary revascularization in a propensity-matched analysis.
Methods

Patients
We studied patients aged ≥18 years who were residents of Ontario, Canada, who presented to an ED with a primary diagnosis of HF. We examined the clinical data abstracted from 3 complementary data sets. Hospitalized HF patients were identified in the Enhanced Feedback For Effective Cardiac Treatment (EFFECT) Phase 1 (from April 1, 1999 , to March 31, 2001 and Phase 2 (from April 1, 2004, to March 31, 2005) studies. 22 From the Emergency Heart Failure Mortality Risk Grade (EHMRG) study, we examined both hospitalized patients and those who were discharged from the ED from April 1, 2004 , to March 31, 2007 Thus, these 3 similar data sets (EFFECT Phases 1 and 2, and EHMRG) included patients who were either hospitalized or discharged home after the ED visit. All patients included in this study were required to meet the Framingham criteria for HF 23 and also have a most responsible diagnosis of HF using the International Classification of Diseases, 9th or 10th revisions (ICD-9-CM code 428 or ICD-10-CA code I50) in the ED or hospital discharge abstract. 24, 25 Ethical approval was obtained from the research ethics board of Sunnybrook Health Sciences Center.
Patients were required to have undergone at least 1 measurement of cTn during the first 24 hours after ED presentation. In case sequential troponins were ordered during this time period, the peak value was chosen to define those who were cTn+ or cTn−. We excluded patients who were hospitalized for an acute coronary syndrome within 14 days before the index ED visit (because troponin values may remain elevated up to 2 weeks after the onset of infarction), those with a serum creatinine concentration >2.0 mg/dL (or 176.8 μmol/L), and those who were palliative or had do-not-resuscitate orders before ED arrival. Unique patients were selected, and thus for those who were included in both the EFFECT and the EHMRG cohorts (eg, had repeat hospital visits), only the first encounter was chosen.
Data Sources
The patient data abstracted for the EFFECT and EHMRG cohorts were linked to administrative databases available in the province of Ontario. ED information was obtained from the National Ambulatory Care Reporting System, which contains records of all ED visits. Mortality was determined using the Registered Persons Database for all deaths. The Canadian Institute for Health Information Discharge Abstract Database was used to identify hospitalizations, procedures, and in-hospital deaths. Dispensation of pharmacological therapies was determined for patients ≥65 years of age using the Ontario Drug Benefit database. We identified fee codes for diagnostic and interventional cardiac procedures using the Ontario Health Insurance Plan physician claims database. All databases have been validated [26] [27] [28] and were linked using the patients' unique, encrypted health card number.
Definitions
cTn was considered elevated if a test drawn within the first 24 hours of the ED visit exceeded the upper limit of the normal range (including indeterminate or gray zone values) according to the assay in use at each institution. We examined troponin tests drawn in a 24-hour window to allow greater sensitivity in detecting those with elevated values among those who may have undergone serial testing for potentially borderline values. The primary outcome of this study was all-cause mortality. Secondary outcomes included hospitalizations for ischemic heart or cardiovascular disease. Ischemic heart disease hospitalizations were defined as admissions with the most responsible diagnosis of angina pectoris, acute myocardial infarction, other acute ischemic heart diseases, and chronic ischemic heart diseases using ICD-9-CM codes 410 to 414 and ICD-10-CA codes I20 to I25. 24, 25 Hospitalizations for cardiovascular disease included all admissions for ischemic heart disease (ICD-9-CM codes 410-414; ICD-10-CA codes I20 to I25), HF (ICD-9-CM code 428; ICD-10-CA code I50), or other cardiovascular conditions (ICD-9-CM codes 390-398, 401-405, 415-417, 420-427, 429-438, 440-448, 451-453, 458, 780.2, 785.4, 785.5, and 798.1; ICD-10-CA codes I00 to I02, I05 to I13, I15, I26 to I28, I30 to I40, I44 to I49, I51, I52, I60 to I74, I77 to I82, I95, I97, R02, R55, R57, and R96). Elective hospital admissions with length of stay of ≤1 day were not counted as an outcome event in hospitalization analyses.
Statistical Analysis
Continuous variables were expressed as median (25th, 75th percentiles) and compared with the Kruskal-Wallis test. Categorical variables were compared using the χ 2 statistic. We used Cox proportional hazards models to estimate the effect of troponin on the risk of the occurrence of outcome events, adjusting simultaneously for both clinical 20 and administratively coded models for mortality and readmission. 29, 30 The model for mortality was adjusted for age, sex, transport by emergency medical services, systolic blood pressure, heart rate, oxygen saturation, serum creatinine, serum potassium, use of metolazone, myocardial infarction, previous HF, coronary artery bypass graft surgery (CABG), percutaneous coronary intervention (PCI), diabetes mellitus, hypertension, active and metastatic cancer, unstable angina, stroke, functional disability, cardiopulmonary respiratory failure and shock, pneumonia, chronic pulmonary obstructive disease, protein calorie malnutrition, dementia, trauma, major psychiatric disorders, peripheral vascular disease, chronic liver disease, chronic atherosclerotic disease, and valvular disease, as determined by comorbidities coded in the index HF visit and by examining all diagnostic codes in the 3 years before the index ED visit. In addition to the above, hospital readmission models were also adjusted for arrhythmias, decubitus/ chronic skin ulcer, other heart diseases, peptic ulcer and other gastrointestinal diseases, severe hematologic disease, urinary tract disorders, end-stage renal disease, and alcohol or drug abuse. All models were also adjusted for the time period: early (1999-2001) versus late (2004) (2005) (2006) (2007) . Time to death was determined from the date of initial ED visit, whereas follow-up for readmission began after the date of hospital or ED discharge. The proportional hazards assumption was tested formally using a Kolmogorov-Smirnov supremum-type test on 1000 resamplings of the cumulative sums of martingale residuals. 31 If a violation of the assumption of the proportionality of hazards was found, we modeled a time-covariate interaction to model the timevarying hazard ratio (HR) explicitly, and instantaneous time-varying HRs with 95% Wald confidence limits were reported.
We conducted 2 separate propensity-score matched analyses in those with cTn+ or cTn− AHFS separately, to estimate the effect of coronary revascularization on survival. We estimated propensity scores for coronary revascularization using the same variables included in the mortality model, in accordance with previous studies suggesting the need for selection of prognostically important covariates. 32 Patients were matched in a 1:2 ratio, such that each patient who was revascularized with either PCI or CABG surgery within 14 days was matched to 2 nonrevascularized patients. Propensity-score matching was performed using a greedy nearest-neighbor matching algorithm on the logit of the propensity score with a caliper width of 0.2 of the SD of the logit of the propensity score. 33 Patients included in this analysis were required to have survived at least 14 days after ED presentation, and time-to-event analysis began on day 14 after the index ED presentation to avoid survivor-treatment bias. Balances in the baseline covariates were evaluated by calculating standardized differences. 34 The effect of revascularization on the risk of an adverse event in the propensity-matched analysis was estimated with a Cox regression model using a robust (sandwich-type) variance estimator to account for matched triplets. 35 A 2-sided probability value <0.05 was considered to be statistically significant. All analyses were performed using SAS 9.2 (SAS Institute, Inc., Cary, NC).
Results
Study Cohort
Among a total of 28 101 unique subjects included in the EFFECT and EHMRG cohorts, cTn was measured in 19 601 individuals. The final study cohort was 13 656 patients ( Figure 1 ), of whom 1845 (13.5%) were cTn+ at ED presentation. Of the 13 329 patients who were discharged alive and were eligible for readmission, 5563 (41.7%) were readmitted for a cardiovascular cause and 1479 (11.1%) were rehospitalized for ischemic heart disease within 2 years. There were 4829 (35.4%) deaths during 2-year follow-up from the time of ED presentation, and a total of 44 812 person-years of follow-up were examined for death. Crude median (25th, 75th percentile) troponin value was 0.05 (0.02, 0.21) among all HF patients studied. Among those with peak troponin values that exceeded the upper limit of the normal range, median values were low: 0.30 (0.09-1.40). Median peak troponin values were 0.04 (0.01-0.10) among those with values below the upper limit of normal range. Of the cohort, 10 339 underwent testing with troponin I (75.5%), 3243 were tested with troponin T (23.7%), and type of troponin was unknown in 74 patients (0.5%). The median (25th, 75th percentile) value of the ratio of the peak cTn/upper limit of normal was 2.80 (1.50, 9.03). Therefore, corresponding raw peak cTn values would be 0.20 (0.11, 0.63) if the upper limit of normal of the troponin assay was 0.07.
Baseline Characteristics and ED Presentation
As shown in Table 1 , cTn+ patients were slightly older, comprised of more men, and exhibited higher prevalence of coronary disease or previous myocardial infarction. Patients with cTn− AHFS had higher frequency of previous coronary revascularization procedures. In the ED, cTn+ patients had more severe presentations, with higher heart rate and respiratory rate, lower oxygen saturation, and chest radiographs consistent with pulmonary edema. Atrial fibrillation was more common in cTn− AHFS, whereas ST-segment deviation and T-wave abnormalities suggestive of ischemia occurred more frequently among cTn+ patients.
Resource Usage and Initial Care
Individuals with cTn+ AHFS more frequently arrived to the ED using emergency medical transport and were more likely to be admitted from the ED. Although cTn+ patients were more often admitted to a higher intensity care setting, the majority of patients who were admitted to an intensive or coronary care unit did not exhibit cTn elevation (68.6%). Patients with cTn+ were more likely to be initially treated with loop diuretics, inotropes, nitroglycerin, and other vasodilators ( Table 2 ).
Diagnosis and Treatment of Coronary Artery Disease
Higher rates of noninvasive stress testing were not observed among those with cTn+; however, rates of coronary angiography were significantly increased among this group (Table  3 ). Rates of revascularization by PCI or CABG surgery were higher among those with cTn+ AHFS, but the majority of patients did not undergo either type of procedure. Among cTn− patients who underwent cardiac catheterization, coronary revascularization procedures were performed in 18.1% at 30 days, 22.0% at 90 days, and 26.9% at 1 year. Coronary revascularization occurred more frequently among cTn+ patients after index cardiac catheterization: 34.5% at 30 days, 40.5% at 90 days, and 46.5% at 1 year (all P<0.001 vs cTn−).
Dispensation of Pharmacological Therapy
Patients aged ≥65 years with cTn+ were more likely to be dispensed angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, β-adrenoreceptor antagonists, clopidogrel, and 3-hydroxy-3-methylglutarylcoenzyme (HMG-CoA) reductase inhibitors ( the drug after this procedure. In contrast, only 13.6% of cTn+ and 7.1% of cTn− patients who did not undergo PCI received clopidogrel within 90 days. There was no difference in use of diuretics between cTn+ and cTn− patients.
Prognostic Effect of Troponin Elevation on Death and Hospitalizations
There was a violation of the assumption of the proportionality of hazards, and therefore instantaneous HRs at specified 
Propensity-Matched Analysis of Coronary Revascularization
In propensity-matched analysis of cTn+ AHFS, we matched 48 patients who underwent a coronary revascularization procedure within 14 days with 95 individuals who did not undergo PCI or CABG. After propensity matching, standardized differences were <0.10 between groups for most covariates (Table 5 ). In propensity-matched analyses, covariates with standardized differences ≥0.10 were adjusted in the Cox regression models. Coronary revascularization within 14 days of the ED visit in cTn+ patients was associated with a reduction in mortality risk with an unadjusted HR in the propensity-score matched sample of 0.20 (95% CI, 0.07-0.63; P=0.006), and a HR of 0.29 (95% CI, 0.09-0.92; P=0.036) adjusting for covariates with standardized difference ≥0.10 during 2 years of follow-up ( Figure 4 ). In the cTn− group, 70 revascularized patients were matched with 140 individuals who did not undergo revascularization within 14 days. Among cTn− patients, coronary revascularization was not associated with a reduction in mortality within 2 years with an unadjusted HR in the propensity-score matched sample of 0.58 (95% CI, 0.34-1.00; P=0.049) and *Small cells (≤5) not shown for metolazone, previous coronary artery bypass graft, previous percutaneous coronary intervention, cardiopulmonary respiratory failure and shock, stroke, renal failure, chronic obstructive pulmonary disease, pneumonia, protein calorie malnutrition, dementia, functional disability, peripheral vascular disease, metastatic cancer, active cancer, trauma, major psychiatric disorders, and chronic liver disease. All of the standardized differences were <0.10 except for cardiopulmonary failure and shock (d=0.12 for cTn+), valvular heart disease (d=0.11 for cTn+), renal failure (d=0.13 for cTn−).
adjusted HR 0.61 (95% CI, 0.36-1.03; P=0.065) compared with those who did not undergo revascularization.
Discussion
The management of AHFS remains challenging with presently few options that can change the early course of the condition. In this study, we found that mildly elevated cTn was a prognostically important marker in acute HF patients with mortality and hospitalization risks that were highest early after initial ED presentation. Although cTn+ patients were more likely to undergo cardiac catheterization and coronary revascularization procedures, the vast majority of patients did not undergo any invasive intervention. Interestingly, in a highly selected subset of patients with AHFS evaluated in a propensity-matched analysis, we found that cTn+ patients who underwent coronary revascularization for obstructive coronary artery disease within 14 days exhibited lower mortality risk than those who were not revascularized. In contrast, there was no reduction in mortality among cTn− patients who underwent coronary revascularization.
Consistent with previous publications, we confirmed the association of cTn with mortality in patients with AHFS, even after extensive covariate adjustment. You et al 18 demonstrated, in 2025 patients admitted with AHFS, that the detection of troponin I was an independent predictor of mortality not only during the hospitalization but also after discharge. In another analysis of >60 000 hospitalized patients with HF, increased risk of in-hospital mortality was demonstrated in those with elevated troponin. 16 Our findings were also consistent with data from clinical registries, which showed that although a history of coronary artery disease is frequent, only a small proportion of individuals are investigated with diagnostic tests, such as coronary angiography during hospital admission. [5] [6] [7] [8] We extended the duration of follow-up for performance of diagnostic tests to 1 year after initial ED presentation and found that both invasive and noninvasive ischemia testing rates remained low.
In an analysis of >40 000 patients admitted with HF in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure registry, those who underwent coronary angiography and were diagnosed with coronary artery disease had higher prescription rates of evidence-based therapies (eg, aspirin, HMG-CoA reductase inhibitors, β-adrenoreceptor antagonists, and angiotensin-converting enzyme inhibitors), PCI, and CABG. 12 In a retrospective analysis, the use of coronary angiography was associated with decreased 90-day mortality and rehospitalization rates, and revascularization of patients with coronary disease resulted in mortality rates that were similar to those without coronary disease. 12 At the current time, invasive angiography for all patients with AHFS is untenable from a health resource and economic perspective. However, our study extends earlier reports by raising the hypothesis that early coronary revascularization among a subset of patients with AHFS may potentially reduce near-term mortality.
The patients in our study cohort were HF patients with mildly elevated cTn, with peak values of this biomarker that did not extend into a range consistent with myocardial infarction in the majority. Thus, they were not patients with acute coronary syndrome complicated by HF, who represent a different clinical spectrum. Our study cohort met the Framingham criteria for HF at the time of ED presentation, and also had a primary discharge diagnosis of HF in the Canadian Institute for Health Information discharge abstract. This cTn+ group comprised more men and diabetics, and had greater prevalence of coronary and peripheral vascular disease. They were also less likely to present in atrial fibrillation, and marginally more had abnormal presentation vital signs. cTn+ patients also had higher use of inotropes that may be responsible in part for myocardial injury and troponin release. 36 Interestingly, previous coronary revascularization procedures were more prevalent among the cTn− group, and those with troponin elevation without previous HF admissions exhibited higher mortality risk than those who were not previously hospitalized for HF. However, there were few clinical, laboratory, and electrocardiographic characteristics that clearly differentiated between cTn+ and cTn− patients at baseline. It is likely that differences in care and treatment between these groups were not driven exclusively by troponin because some cTn− patients underwent cardiac catheterization and noninvasive stress testing. The increased rates of death and rehospitalization likely reflect the destabilizing and complicating impact of active coronary ischemia, leading to the need for care of recurrent AHFS and cardiovascular disease. Although several mechanisms for troponin release are probably active in an individual patient with HF, 14 myocardial ischemia as the main reason for detectable troponin is supported by increased prevalence of previous revascularization procedures among cTn− patients at presentation, higher rates of coronary revascularization procedures after cardiac catheterization among cTn+ than cTn− patients, and improved survival in a small cTn+ subcohort undergoing early coronary revascularization in propensity-matched analysis.
The implications of this study are underscored by the paucity of treatment options that can improve the course of AHFS.
Our study suggests that in AHFS, troponin is not simply a bystander that correlates with the degree of patient sickness. Instead, elevation of this biomarker in the acute setting may indicate the active contribution of ischemia to HF prognosis as demonstrated by the increased risk of rehospitalization and death. Patients with elevation of this biomarker should be considered for further investigation with noninvasive testing or coronary angiography irrespective of left-ventricular function, and optimization of medical therapy should be performed. Furthermore, our study promotes the hypothesis that it may be reasonable to consider coronary revascularization in selected patients with cTn+ AHFS if coronary ischemia and evidence of anatomic disease are present.
There are some notable limitations of this study. Troponin measurement was not standard of care during the time horizon of this study; therefore, a sizeable proportion of patients without such testing were excluded. Although high-sensitivity troponin assays were not available during the time frame of the EFFECT and EHMRG studies, the findings of the current study may directly extend to the use of this biomarker in HF. The propensity risk analysis allows only for adjustment based on measured variables while important factors, such as the extent and severity of ischemia or coronary artery disease, and how the decision was made to refer individuals to angiography were not evaluated. However, these factors may have been directly associated with the probability of coronary angiography and revascularization. Although it is conceivable that individuals with cTn+ had more ischemia or severe coronary disease on angiography, we were unable to determine whether such an association was present. Finally, the intriguing results from the propensity-matched analysis of early revascularization were also limited by the low rates of procedures conducted in an acute time frame of 14 days after ED presentation.
Conclusions
In conclusion, patients with cTn+ AHFS demonstrated higher risk of rehospitalization and death in long-term follow-up. Although cTn+ patients received higher rates of prescription of evidence-based therapies and use of invasive procedures for the diagnosis and treatment of ischemic heart disease, the overall rates were low compared with the adverse outcomes experienced by this group. Our study generates the hypothesis that presence of elevated troponin may help identify patients with AHFS who may benefit from further investigation for coronary artery disease and early coronary revascularization. Further studies are needed to determine the best strategies for identifying patients who would benefit from referral to coronary angiography and possible revascularization procedure.
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